CytoMed Therapeutics (GDTC) Assets Average (2022 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Assets Average for 4 consecutive years, with $6.9 million as the latest value for Q4 2025.

  • Quarterly Assets Average fell 17.93% to $6.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.9 million through Dec 2025, down 17.93% year-over-year, with the annual reading at $6.8 million for FY2025, 18.11% down from the prior year.
  • Assets Average hit $6.9 million in Q4 2025 for CytoMed Therapeutics, down from $8.4 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $8.4 million in Q4 2024 to a low of $4.1 million in Q4 2022.
  • Historically, Assets Average has averaged $6.5 million across 4 years, with a median of $6.7 million in 2023.
  • Biggest five-year swings in Assets Average: skyrocketed 56.73% in 2023 and later dropped 17.93% in 2025.
  • Year by year, Assets Average stood at $4.1 million in 2022, then surged by 56.73% to $6.5 million in 2023, then increased by 29.41% to $8.4 million in 2024, then fell by 17.93% to $6.9 million in 2025.
  • Business Quant data shows Assets Average for GDTC at $6.9 million in Q4 2025, $8.4 million in Q4 2024, and $6.5 million in Q4 2023.